# Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

> **NCT01131325** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- CML
- Philadelphia Chromosome Positive (Ph+)
- Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels

## Interventions

- **DRUG:** nilotinib

## Key facts

- **NCT ID:** NCT01131325
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10-21
- **Primary completion:** 2011-05-12
- **Final completion:** 2011-05-12
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131325, "Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01131325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*